Alvotech will conduct a business update conference call and live webcast on Thursday March 27, 2025, at 8:00 am ET (12:00pm ...

Approximately 45,000 patients have begun using omalizumab for food allergy in the year since its approval by the FDA, Ahmar Iqbal, MD, therapeutic area lead for respiratory and influenza at Genentech, ...

Blue Cross Blue Shield of Texas will stop covering certain asthma infusion treatments in clinics, obliging patients to self-inject the drugs at home. The provider will cut this coverage from its plans ...

People with severe asthma insured by BlueCross BlueShield of Illinois may soon face a new hurdle in accessing a treatment ...

A 27-year-old woman developed a rare cold allergy after Covid-19 and had her first anaphylaxis attack after a McDonald’s ...

Hanna’s first anaphylaxis attack was triggered by a McDonald’s milkshake and a McFlurry in December 2020, both now off-limits foodstuffs along with coconut Little Moons, which she misses. After ...

For Hanna Newnham, 27, her one time McDonald's favourites are now completely off limits as is exercising outdoors during the ...

A 27-year-old has been left unable to drink chilled beverages or exercise outdoors in winter after developing a rare cold ...

Celltrion Inc. is on a biosimilar roll with the U.S. FDA this month, having gained clearance of Stoboclo and Osenvelt as products referencing Amgen Inc.’s biologic, denosumab (Prolia, Xgeva), along ...

The FDA approved omalizumab-igec (Omlyclo) as the first biosimilar for omalizumab (Xolair) and the first for any respiratory condition in the U.S., drugmaker Celltrion announced Monday. The ...

Omlyclo, a biosimilar to Xolair, is indicated for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, immunoglobulin E-mediated food allergies, and chronic ...